These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23259389)

  • 1. [Anti-EGFR antibody therapy for colorectal cancer].
    Ishikawa T; Uetake H; Sugihara K
    Nihon Rinsho; 2012 Dec; 70(12):2152-8. PubMed ID: 23259389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
    Song QB; Wang Q; Hu WG
    World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
    Tougeron D; Cortes U; Ferru A; Villalva C; Silvain C; Tourani JM; Levillain P; Karayan-Tapon L
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):397-403. PubMed ID: 23765179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.
    Russo A; Rizzo S; Bronte G; Silvestris N; Colucci G; Gebbia N; Bazan V; Fulfaro F
    Oncology; 2009; 77 Suppl 1():57-68. PubMed ID: 20130433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
    N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
    Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
    Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
    Prenen H; De Schutter J; Jacobs B; De Roock W; Biesmans B; Claes B; Lambrechts D; Van Cutsem E; Tejpar S
    Clin Cancer Res; 2009 May; 15(9):3184-8. PubMed ID: 19366826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
    Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.
    Perkins G; Pilati C; Blons H; Laurent-Puig P
    Pharmacogenomics; 2014 May; 15(7):1043-52. PubMed ID: 24956256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer].
    Soeda H; Shimodaira H; Ishioka C
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1079-83. PubMed ID: 21772090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
    Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.
    Molinari F; Felicioni L; Buscarino M; De Dosso S; Buttitta F; Malatesta S; Movilia A; Luoni M; Boldorini R; Alabiso O; Girlando S; Soini B; Spitale A; Di Nicolantonio F; Saletti P; Crippa S; Mazzucchelli L; Marchetti A; Bardelli A; Frattini M
    Clin Cancer Res; 2011 Jul; 17(14):4901-14. PubMed ID: 21632860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The current status of development of anti-EGFR antibodies].
    Ura T
    Gan To Kagaku Ryoho; 2010 May; 37(5):777-81. PubMed ID: 20495305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.
    Kim R; Kubal T
    Clin Colorectal Cancer; 2012 Jun; 11(2):85-7. PubMed ID: 22169039
    [No Abstract]   [Full Text] [Related]  

  • 18. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
    Fabian P; Berkovcová J
    Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.